We’re not out of the woods yet, but the major indices are turning green again and psychedelics, recently a relative investment pariah, are getting some love from investors. The…
SEEL.Q
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Another Psychedelics article, and once again I try to answer the question: is it time to buy the dips in Psychedelics. My views remain the same. In this market,…
SPL026 Small Pharma (DMT.V), a psychedelics company focusing on DMT announced today it’s completed Phase 1 for its drug candidate SPL026, (a DMT derivative) for the treatment of Major…